Literature DB >> 3755169

Characterization of muscarinic receptors of the rabbit ear artery smooth muscle and endothelium.

M R Hynes, W Banner, H I Yamamura, S P Duckles.   

Abstract

Muscarinic receptors of the rabbit ear artery were characterized by observing the effect of the subtype selective antagonist pirenzepine on functional responses and radioligand binding. Pirenzepine has been shown to bind with high affinity to muscarinic receptors of certain brain regions and peripheral ganglia (M1 subtype) and with low affinity to receptors of the heart and upper gastrointestinal tract (M2 subtype). The affinity (pKB) of pirenzepine for the muscarinic sites of the endothelium was determined by the competitive antagonism of the relaxation response to methacholine. Schild analysis gave a pKB of 6.5 (320 nM) which is consistent with the low affinity, M2, subtype of muscarinic receptor. Removal of the endothelium eliminates any response to muscarinic agonists but does not decrease the density of muscarinic binding sites determined by binding of the specific ligand (-)-[3H]quinuclidinyl benzilate. This indicates a second group of muscarinic receptors most probably located on vascular smooth muscle cells for which there is no known function. The pKi for pirenzepine at these sites, as determined by the inhibition of (-)-[3H]quinuclidinyl benzilate binding, was 6.26 (550 nM) which is also consistent with a low affinity subtype. Thus, both types of vascular muscarinic binding sites, those on the endothelium which mediate relaxation and those on the vascular smooth muscle cells, are of the low affinity, M2, subtype.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3755169

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

1.  Binding of muscarine receptor antagonists to pig coronary smooth muscle.

Authors:  I Rinner; H N Doods; K J van Charldorp; D Davidesko; P A van Zwieten
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-02       Impact factor: 3.000

2.  M1 and M3 muscarinic receptors in human pulmonary arteries.

Authors:  X Norel; L Walch; M Costantino; C Labat; I Gorenne; E Dulmet; F Rossi; C Brink
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

3.  Radioligand binding to muscarinic receptors of bovine aortic endothelial cells.

Authors:  F Brunner; W R Kukovetz
Journal:  Br J Pharmacol       Date:  1991-02       Impact factor: 8.739

4.  Methoctramine selectively blocks cardiac muscarinic M2 receptors in vivo.

Authors:  J Wess; P Angeli; C Melchiorre; U Moser; E Mutschler; G Lambrecht
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-09       Impact factor: 3.000

5.  Cyclic GMP-independent relaxation and hyperpolarization with acetylcholine in guinea-pig coronary artery.

Authors:  D M Eckman; J S Weinert; I L Buxton; K D Keef
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

6.  Prejunctional muscarine receptors in the rabbit ear artery differ from M1, M2 and M3 muscarine receptors.

Authors:  S A Darroch; L K Choo; F Mitchelson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1992-03       Impact factor: 3.000

7.  The interaction of parafluorohexahydrosiladiphenidol at muscarinic receptors in vitro.

Authors:  R M Eglen; A D Michel; W W Montgomery; E A Kunysz; C A Machado; R L Whiting
Journal:  Br J Pharmacol       Date:  1990-04       Impact factor: 8.739

8.  Release of endothelium-derived hyperpolarizing factor (EDHF) by M3 receptor stimulation in guinea-pig coronary artery.

Authors:  A K Hammarström; H C Parkington; H A Coleman
Journal:  Br J Pharmacol       Date:  1995-07       Impact factor: 8.739

9.  Inhibition of hypoxia-induced relaxation of rabbit isolated coronary arteries by NG-monomethyl-L-arginine but not glibenclamide.

Authors:  C Jiang; P Collins
Journal:  Br J Pharmacol       Date:  1994-03       Impact factor: 8.739

10.  The interaction of methoctramine and himbacine at atrial, smooth muscle and endothelial muscarinic receptors in vitro.

Authors:  R M Eglen; W W Montgomery; I A Dainty; L K Dubuque; R L Whiting
Journal:  Br J Pharmacol       Date:  1988-12       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.